Physician profile
Patrick M Mcgowan
NPI 1730569310
$3,337.43
in general payments reported to CMS, 2019-2025
31 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $736 · 2021: $428 · 2022: $456 · 2023: $361 · 2024: $563 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $509.54 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $462.13 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $448.47 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $323.70 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $277.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $156.51 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Exact Sciences Corporation | $144.95 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $137.52 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $119.17 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $103.76 | 2024-2025 | Voquezna |
| Abbvie INC. | $78.16 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $63.52 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.37 | 2020-2023 | |
| Glaxosmithkline, LLC. | $43.01 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $38.66 | 2024-2025 | Zoryve |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $36.86 | 2021-2023 | Epclusa |
| Genzyme Corporation | $36.32 | 2025 | |
| Biogen, INC. | $35.28 | 2024-2025 | Skyclarys |
| Dexcom, INC. | $32.96 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.69 | 2020-2025 | Xifaxan |
| Sanofi Pasteur INC. | $30.92 | 2020-2023 | |
| Genentech USA, INC. | $27.65 | 2020-2021 | |
| Allergan, INC. | $26.67 | 2019-2021 | |
| Antares Pharma, INC. | $23.63 | 2025 | Xyosted |
| Philips North America LLC | $18.80 | 2020 | |
| Astellas Pharma US INC | $15.48 | 2020 | |
| Eisai INC. | $14.88 | 2021 | |
| Abiomed | $14.87 | 2025 | |
| Ironwood Pharmaceuticals, INC | $13.34 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.59 | 2022 | |
| Currax Pharmaceuticals LLC | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcgowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.